Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

Rhea-AI Summary

Nuvectis Pharma announced that CEO Ron Bentsur will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:30 PM PT (5:30 PM ET). The conference will showcase the company's focus on innovative precision medicines for oncology. Nuvectis is developing NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in IND-enabling pre-clinical testing. More details can be found on their website.

News Market Reaction – NVCT

+4.60%

+4.60% Session move

In the trading session that priced this news, NVCT gained 4.60%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) --

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.

Event	34th Annual Roth Conference
Date	March 15, 2022
Time	2:30 PM Pacific Time (5:30 PM Eastern Time)
Format	Fireside Chat
Link	https://wsw.com/webcast/roth43/nvct/1845484

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact:

LifeSci Advisors on behalf of Nuvectis Pharma, Inc.

Eric Goldstein

Tel: 646-791-9729

egoldstein@lifesciadvisors.com

FAQ

When will Nuvectis Pharma's CEO speak at the Roth Conference?

Ron Bentsur, CEO of Nuvectis Pharma, will speak at the Roth Conference on March 15, 2022.

What time is the fireside chat at the Roth Conference?

The fireside chat will take place at 2:30 PM Pacific Time (5:30 PM Eastern Time).

Where can I find more information about Nuvectis Pharma?

More information about Nuvectis Pharma can be found on their website at www.nuvectis.com.

What is Nuvectis Pharma focused on?

Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions.

What products are in Nuvectis Pharma's pipeline?

Nuvectis Pharma's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in pre-clinical testing.